A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance

American Journal of Medicine

Volumn 105, Issue 1, 1998, Pages 7-11

  Revankar, Sanjay G ^a   Kirkpatrick, William R ^a   McAtee, Robert K ^a   Dib, Olga P ^a   Fothergill, Annette W ^a   Redding, Spencer W ^a   Rinaldi, Michael G ^b   Hilsenbeck, Susan G ^a   Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; FOLLOW UP; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THRUSH;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUCONAZOLE; HUMANS; MALE; OROPHARYNX; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0032125793     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00137-5     Document Type: Article

References (25)

1. De Wit S., Weerts D., Goossens H., Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1:1989;746-747.
2. Koletar S.L., Russell J.A., Fass R.J., Plouffe J.F. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemo. 34:1990;2267-2268.
3. Just-Nubling G., Gentschew G., Meibner K., et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis. 10:1991;917-921.
4. Rex J.H., Pfaller M.A., Barry A.L., et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemo. 39:1995;40-44.
5. Law D., Moore C.B., Wardle H.M., et al. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chem. 34:1994;659-668.
6. Redding S., Smith J., Farinacci G., et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS documentation by in vitro susceptibility testing and DNA subtype analysis . Clin Infect Dis. 18:1994;240-242.
7. White A., Goetz M.B. Azole-resistant Candida albicans report of two cases of resistance to fluconazole and review . Clin Infect Dis. 19:1994;687-692.
8. Ruhnke M., Eigler A., Tennagen I., et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 32:1994;2092-2098.
9. Revankar S.G., Kirkpatrick W.R., McAtee R.K., et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 174:1996;821-827.
10. Maenza J.R., Keruly J.C., Moore R.D., et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 173:1996;219-225.
11. Millon L., Manteaux A., Reboux G., et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients persistence of Candida albicans strains with the same genotype . J Clin Microbiol. 32:1994;1115-1118.
12. Sanguineti A., Carmichael J.K., Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med. 153:1993;1122-1124.
13. Johnson E.M., Warnock D.W., Luker J., et al. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J Antimicrob Chemo. 35:1995;103-114.
14. Heald A.E., Cox G.M., Schell W.A., et al. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS. 10:1996;263-268.
15. Patterson T.F., Revankar S.G., Kirkpatrick W.R., et al. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol. 34:1996;1794-1797.
16. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. Wayne, Penn: NCCLS, 1997; document M27-A.
17. Collett D. Modelling Survival Data in Medical Research. 1994;Chapman & Hall, New York.
18. Stevens D.A., Greene S.I., Lang O.S. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Arch Intern Med. 151:1991;2458-2464.
19. Marriott D.J.E., Jones P.D., Hoy J.F., et al. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. Med J Australia. 158:1993;312-316.
20. Powderly W.G., Finkelstein D.M., Feinberg J., et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NEJM. 332:1995;700-705.
21. Sangeorzan J.A., Bradley S.F., He X., et al. Epidemiology of oral candidiasis in HIV-infected patients colonization, infection, treatment, and emergence of fluconazole resistance . Am J Med. 97:1994;339-346.
22. Maenza J.R., Merz W.G., Romagnoli M.J., et al. Infection due to fluconazole-resistant Candida in patients with AIDS prevalence and microbiology . Clin Infect Dis. 24:1997;28-34.
23. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 24:1997;235-247.
24. Revankar S.G., Dib O.P., Kirkpatrick W.R., et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 26:1998;960-963.
25. Schuman P., Capps L., Peng G., et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med. 126:1997;689-696.